Compare SMX Security Matters plc (SMX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs State Street SPDR S&P Biotech ETF — how do they compare? SMX Security Matters plc trades at $17.92 (market cap $19.09M), while State Street SPDR S&P Biotech ETF trades at $159.88. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| SMX | XBI | |
|---|---|---|
Market Cap | $19.09M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $74.08K | $169.55 |
52-Week Low | $12.87 | $93.43 |
Enterprise Value | -$12.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX trades at $17.88, down 8.21% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $169.18 million for 2025, with negative cash flow from operations but positive net cash flow due to financing. Recent news highlights expansion of its digital material passport platform for plastics and precious metals, targeting sustainability and supply chain verification markets.
The outlook hinges on commercialization success amid steep losses. Opportunities exist in regulatory tailwinds for recycled materials, but high cash burn and negative ROE pose significant risks. Investor sentiment is cautiously optimistic due to technology potential, yet profitability remains a distant milestone.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
